{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:19:48Z","timestamp":1787026788994,"version":"build-2736575974"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Med"],"abstract":"<jats:p>Autoimmune cholestatic liver disease includes both Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC). Both conditions result in impairment of hepatic bile flow ultimately leading to chronic liver injury, liver fibrosis and eventually end stage cirrhosis. Early and accurate diagnosis are important for the risk stratification, follow up and management of these patients. The underlying pathogenesis of these conditions have not been completely resolved and poses a barrier for the development of new diagnostic and prognostics tools. Current research work suggests that the pathogenesis of autoimmune cholestatic liver disease results from environmental, genetic, and a large component of underlying immune dysfunction. While the current available serum biomarkers and imaging modalities showcases progression in precision medicine for the management of autoimmune cholestatic liver disease, development of new biomarkers are still an area of need in this field. In this review, we will discuss the current and emerging biomarkers in patients with PBC, PSC, and a special population that exhibit overlap syndrome with autoimmune hepatitis (AIH). The use of these biomarkers for diagnosis and prognosis of these patients will be reviewed through the lens of the current understanding of the complex immune pathophysiology of these conditions.<\/jats:p>","DOI":"10.3389\/fmmed.2022.914505","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T03:38:24Z","timestamp":1657251504000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["A Review on Biomarkers for the Evaluation of Autoimmune Cholestatic Liver Diseases and Their Overlap Syndromes"],"prefix":"10.3389","volume":"2","author":[{"given":"Henry H.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin J.","family":"Fritzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jhep.2003.11.033","article-title":"Primary Biliary Cirrhosis: An Infectious Disease Caused by Chlamydia Pneumoniae?","volume":"40","author":"Abdulkarim","year":"2004","journal-title":"J. Hepatology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cgh.2018.08.008","article-title":"Altered Microbiome in Patients with Cirrhosis and Complications","volume":"17","author":"Acharya","year":"2019","journal-title":"Clin. Gastroenterology Hepatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The Gut-Liver Axis in Liver Disease: Pathophysiological Basis for Therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J. Hepatology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/hep.510300101","article-title":"Primary Sclerosing Cholangitis","volume":"30","author":"Angulo","year":"1999","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0168-8278(00)80061-6","article-title":"Serum Autoantibodies in Patients with Primary Sclerosing Cholangitis","volume":"32","author":"Angulo","year":"2000","journal-title":"J. Hepatology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"002264","DOI":"10.12890\/2021_002264","article-title":"Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome Triggered by COVID-19","volume":"8","author":"Balraj Singh","year":"2021","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41575-019-0125-y","article-title":"Cholangiocyte Pathobiology","volume":"16","author":"Banales","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/diagnostics11040587","article-title":"Analysis of Autoantibodies Against Promyelocytic Leukemia Nuclear Body Components and Biochemical Parameters in Sera of Patients with Primary Biliary Cholangitis","volume":"11","author":"Bauer","year":"2021","journal-title":"Diagnostics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap Syndromes: The International Autoimmune Hepatitis Group (IAIHG) Position Statement on a Controversial Issue","volume":"54","author":"Boberg","year":"2011","journal-title":"J. Hepatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0168-8278(03)00501-4","article-title":"Microbial Mimics Are Major Targets of Crossreactivity with Human Pyruvate Dehydrogenase in Primary Biliary Cirrhosis","volume":"40","author":"Bogdanos","year":"2004","journal-title":"J. Hepatology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1053\/j.gastro.2003.09.034","article-title":"Autoreactivity to Lipoate and a Conjugated Form of Lipoate in Primary Biliary Cirrhosis","volume":"125","author":"Bruggraber","year":"2003","journal-title":"Gastroenterology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41577-019-0268-7","article-title":"Host-Microbiota Interactions in Inflammatory Bowel Disease","volume":"20","author":"Caruso","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e21887","DOI":"10.1097\/MD.0000000000021887","article-title":"Value of Anti-p53 Antibody as a Biomarker for Hepatocellular Carcinoma","volume":"99","author":"Chang","year":"2020","journal-title":"Medicine"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British Society of Gastroenterology and UK-PSC Guidelines for the Diagnosis and Management of Primary Sclerosing Cholangitis","volume":"68","author":"Chapman","year":"2019","journal-title":"Gut"},{"key":"B15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary Biliary Cirrhosis-Autoimmune Hepatitis Overlap Syndrome: Clinical Features and Response to Therapy","volume":"28","author":"Chazouill\u00e8res","year":"1998","journal-title":"Hepatology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jhep.2005.10.017","article-title":"Long Term Outcome and Response to Therapy of Primary Biliary Cirrhosis-Autoimmune Hepatitis Overlap Syndrome","volume":"44","author":"Chazouill\u00e8res","year":"2006","journal-title":"J. Hepatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1055\/s-2007-1007185","article-title":"Nuclear Envelope Protein Autoantibodies in Primary Biliary Cirrhosis","volume":"17","author":"Courvalin","year":"1997","journal-title":"Semin. Liver Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/cld.642","article-title":"IgG4-Related Sclerosing Cholangitis","volume":"10","author":"Culver","year":"2017","journal-title":"Clin. Liver Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/modpathol.2009.94","article-title":"IgG4-Associated Cholangitis: A Comparative Histological and Immunophenotypic Study with Primary Sclerosing Cholangitis on Liver Biopsy Material","volume":"22","author":"Deshpande","year":"2009","journal-title":"Mod. Pathol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","article-title":"Primary Sclerosing Cholangitis","volume":"391","author":"Dyson","year":"2018","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/apt.13154","article-title":"A Comprehensive Assessment of Environmental Exposures Among 1000 North American Patients with Primary Sclerosing Cholangitis, with and without Inflammatory Bowel Disease","volume":"41","author":"Eaton","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00109-004-0554-z","article-title":"Autoantigens of the Nuclear Pore Complex","volume":"82","author":"Enarson","year":"2004","journal-title":"J. Mol. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL Clinical Practice Guidelines: Management of Cholestatic Liver Diseases","volume":"51","year":"2009","journal-title":"J. Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: The Diagnosis and Management of Patients with Primary Biliary Cholangitis","volume":"67","year":"2017","journal-title":"J. Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41579-020-0433-9","article-title":"Gut Microbiota in Human Metabolic Health and Disease","volume":"19","author":"Fan","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.autrev.2010.09.025","article-title":"Historical Perspectives on the Discovery and Elucidation of Autoantibodies to Centromere Proteins (CENP) and the Emerging Importance of Antibodies to CENP-F","volume":"10","author":"Fritzler","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3109\/08916934.2013.801461","article-title":"Clinical Significance of the Fluctuation of Primary Biliary Cirrhosis-Related Autoantibodies During the Course of the Disease","volume":"46","author":"Gatselis","year":"2013","journal-title":"Autoimmunity"},{"key":"B28","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.gastro.2007.12.009","article-title":"Immunoglobulin G4-Associated Cholangitis: Clinical Profile and Response to Therapy","volume":"134","author":"Ghazale","year":"2008","journal-title":"Gastroenterology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/ajg.2009.596","article-title":"PML Nuclear Body Component Sp140 Is a Novel Autoantigen in Primary Biliary Cirrhosis","volume":"105","author":"Granito","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1007590","DOI":"10.1371\/journal.ppat.1007590","article-title":"PML Nuclear Body-Residing Proteins Sequentially Associate with HPV Genome After Infectious Nuclear Delivery","volume":"15","author":"Guion","year":"2019","journal-title":"PLoS Pathog."},{"key":"B31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/liv.14688","article-title":"Antibodies to Gp210 and Understanding Risk in Patients with Primary Biliary Cholangitis","volume":"41","author":"Haldar","year":"2021","journal-title":"Liver Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1053\/jhep.2001.22653","article-title":"Molecular Identification of Bacterial 16S Ribosomal RNA Gene in Liver Tissue of Primary Biliary Cirrhosis: Is Propionibacterium Acnes Involved in Granuloma Formation?","volume":"33","author":"Harada","year":"2001","journal-title":"Hepatology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1136\/gutjnl-2019-319057","article-title":"Number Needed to Treat with Ursodeoxycholic Acid Therapy to Prevent Liver Transplantation or Death in Primary Biliary Cholangitis","volume":"69","author":"Harms","year":"2020","journal-title":"Gut"},{"key":"B34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1155\/2012\/890698","article-title":"Clinical Significance of Autoantibodies to P53 Protein in Patients with Autoimmune Liver Diseases","volume":"26","author":"Himoto","year":"2012","journal-title":"Can. J. Gastroenterology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC Primary Biliary Cholangitis Treatment and Management Guidelines","volume":"67","author":"Hirschfield","year":"2018","journal-title":"Gut"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e101916","DOI":"10.1371\/journal.pone.0101916","article-title":"Meta-Analysis Assessment of GP210 and SP100 for the Diagnosis of Primary Biliary Cirrhosis","volume":"9","author":"Hu","year":"2014","journal-title":"PLoS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1515\/cclm-2013-0926","article-title":"The Accuracy of the Anti-Mitochondrial Antibody and the M2 Subtype Test for Diagnosis of Primary Biliary Cirrhosis: A Meta-Analysis","volume":"52","author":"Hu","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/s0168-8278(00)00040-4","article-title":"Autoantibodies Against Nuclear Pore Complexes Are Associated with More Active and Severe Liver Disease in Primary Biliary Cirrhosis","volume":"34","author":"Invernizzi","year":"2001","journal-title":"J. Hepatology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1055\/s-2005-916321","article-title":"Antinuclear Antibodies in Primary Biliary Cirrhosis","volume":"25","author":"Invernizzi","year":"2005","journal-title":"Semin. Liver Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.14309\/ajg.0000000000001280","article-title":"Ursodeoxycholic Acid Response Is Associated with Reduced Mortality in Primary Biliary Cholangitis with Compensated Cirrhosis","volume":"116","author":"John","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/hep.23667","article-title":"Carriage of a Tumor Necrosis Factor Polymorphism Amplifies the Cytotoxic T-Lymphocyte Antigen 4 Attributed Risk of Primary Biliary Cirrhosis: Evidence for a Gene-Gene Interaction","volume":"52","author":"Juran","year":"2010","journal-title":"Hepatology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/annrheumdis-2020-218881","article-title":"Anti-Centromere Antibodies Target Centromere-Kinetochore Macrocomplex: A Comprehensive Autoantigen Profiling","volume":"80","author":"Kajio","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary Biliary Cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary Sclerosing Cholangitis - A Comprehensive Review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J. Hepatology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1053\/gast.2000.20197","article-title":"Epidemiology and Natural History of Primary Biliary Cirrhosis in a U.S. Community","volume":"119","author":"Kim","year":"2000","journal-title":"Gastroenterology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.pathol.2019.07.002","article-title":"The Significance of ANCA Positivity in Patients with Inflammatory Bowel Disease","volume":"51","author":"Lee","year":"2019","journal-title":"Pathology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/gutjnl-2018-317791","article-title":"Fungi Participate in the Dysbiosis of Gut Microbiota in Patients with Primary Sclerosing Cholangitis","volume":"69","author":"Lemoinne","year":"2020","journal-title":"Gut"},{"key":"B48","doi-asserted-by":"publisher","first-page":"5326","DOI":"10.4049\/jimmunol.170.10.5326","article-title":"Immunization with a Xenobiotic 6-Bromohexanoate Bovine Serum Albumin Conjugate Induces Antimitochondrial Antibodies","volume":"170","author":"Leung","year":"2003","journal-title":"J. Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1946366","DOI":"10.1080\/19490976.2021.1946366","article-title":"Alterations in Microbiota and Their Metabolites Are Associated with Beneficial Effects of Bile Acid Sequestrant on Icteric Primary Biliary Cholangitis","volume":"13","author":"Li","year":"2021","journal-title":"Gut Microbes"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1136\/gutjnl-2018-316670","article-title":"Intestinal Dysbiosis Augments Liver Disease Progression via NLRP3 in a Murine Model of Primary Sclerosing Cholangitis","volume":"68","author":"Liao","year":"2019","journal-title":"Gut"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.3748\/wjg.v26.i21.2768","article-title":"Gut Microbiome in Primary Sclerosing Cholangitis: A Review","volume":"26","author":"Little","year":"2020","journal-title":"Wjg"},{"key":"B52","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/hep.23783","article-title":"Biliary Apotopes and Anti-Mitochondrial Antibodies Activate Innate Immune Responses in Primary Biliary Cirrhosis","volume":"52","author":"Lleo","year":"2010","journal-title":"Hepatology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1111\/1462-2920.13401","article-title":"Alterations and Correlations of the Gut Microbiome, Metabolism and Immunity in Patients with Primary Biliary Cirrhosis","volume":"18","author":"Lv","year":"2016","journal-title":"Environ. Microbiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1056\/NEJMra1600266","article-title":"The Human Intestinal Microbiome in Health and Disease","volume":"375","author":"Lynch","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines from the American Association for the Study of Liver Diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10157-012-0724-1","article-title":"Anti-Centromere Antibody Is an Independent Risk Factor for Chronic Kidney Disease in Patients with Primary Biliary Cirrhosis","volume":"17","author":"Mandai","year":"2013","journal-title":"Clin. Exp. Nephrol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.3748\/wjg.v26.i23.3126","article-title":"Review of Primary Sclerosing Cholangitis with Increased IgG4 Levels","volume":"26","author":"Manganis","year":"2020","journal-title":"Wjg"},{"key":"B58","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1016\/j.jhep.2015.03.005","article-title":"Autoimmune Hepatitis - Update 2015","volume":"62","author":"Manns","year":"2015","journal-title":"J. Hepatology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/eji.1830200426","article-title":"T Cell Receptor Gene Rearrangements of T Lymphocytes Infiltrating the Liver in Chronic Active Hepatitis B and Primary Biliary Cirrhosis (PBC): Oligoclonality of PBC-Derived T Cell Clones","volume":"20","author":"Moebius","year":"1990","journal-title":"Eur. J. Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1002\/hep.24247","article-title":"Incidence of Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis","volume":"53","author":"Molodecky","year":"2011","journal-title":"Hepatology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/hep.1840170310","article-title":"Prevalence and Characterization of Neutrophil Cytoplasmic Antibodies in Autoimmune Liver Diseases","volume":"17","author":"Mulder","year":"1993","journal-title":"Hepatology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1080\/08916930802709133","article-title":"Multiple Nuclear Dots and Rim-Like\/Membranous IgG Isotypes in Primary Biliary Cirrhosis","volume":"42","author":"Muratori","year":"2009","journal-title":"Autoimmunity"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/ajg.2009.126","article-title":"The Serological Profile of the Autoimmune Hepatitis\/Primary Biliary Cirrhosis Overlap Syndrome","volume":"104","author":"Muratori","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1572-0241.2003.07257.x","article-title":"Characterization and Clinical Impact of Antinuclear Antibodies in Primary Biliary Cirrhosis","volume":"98","author":"Muratori","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.cca.2012.03.020","article-title":"Diagnostic and Clinical Utility of Antibodies Against the Nuclear Body Promyelocytic Leukaemia and Sp100 Antigens in Patients with Primary Biliary Cirrhosis","volume":"413","author":"Mytilinaiou","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"B66","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","article-title":"Gut Pathobionts Underlie Intestinal Barrier Dysfunction and Liver T Helper 17 Cell Immune Response in Primary Sclerosing Cholangitis","volume":"4","author":"Nakamoto","year":"2019","journal-title":"Nat. Microbiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and Anti-Centromere Antibodies Are Different Risk Factors for the Progression of Primary Biliary Cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jhep.2004.11.016","article-title":"Antibody Titer to Gp210-C Terminal Peptide as a Clinical Parameter for Monitoring Primary Biliary Cirrhosis","volume":"42","author":"Nakamura","year":"2005","journal-title":"J. Hepatology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e0193960","DOI":"10.1371\/journal.pone.0193960","article-title":"Evaluation of Classical and Novel Autoantibodies for the Diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS)","volume":"13","author":"Nguyen","year":"2018","journal-title":"PLoS One"},{"key":"B70","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/liv.12690","article-title":"Anti-Kelch-Like 12 and Anti-Hexokinase 1: Novel Autoantibodies in Primary Biliary Cirrhosis","volume":"35","author":"Norman","year":"2015","journal-title":"Liver Int."},{"key":"B71","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-2249.2004.02432.x","article-title":"The Nuclear Pore Complex Protein Tpr Is a Common Autoantigen in Sera that Demonstrate Nuclear Envelope Staining by Indirect Immunofluorescence","volume":"136","author":"Ou","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41584-020-0500-7","article-title":"IgG4-Related Disease: An Update on Pathophysiology and Implications for Clinical Care","volume":"16","author":"Perugino","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41584-020-0480-7","article-title":"New Insights into the Role of Antinuclear Antibodies in Systemic Lupus Erythematosus","volume":"16","author":"Pisetsky","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis","volume":"330","author":"Poupon","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/ecco-jcc\/jjaa021","article-title":"A Pilot Integrative Analysis of Colonic Gene Expression, Gut Microbiota, and Immune Infiltration in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Association of Disease with Bile Acid Pathways","volume":"14","author":"Quraishi","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"B76","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/cei.13397","article-title":"Immunological Mechanisms Underpinning Faecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease","volume":"199","author":"Quraishi","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.14309\/ajg.0000000000000690","article-title":"Novel Anti-Hexokinase 1 Antibodies Are Associated with Poor Prognosis in Patients with Primary Biliary Cholangitis","volume":"115","author":"Reig","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/apt.15375","article-title":"Consistent Alterations in Faecal Microbiomes of Patients with Primary Sclerosing Cholangitis Independent of Associated Colitis","volume":"50","author":"R\u00fchlemann","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1053\/jhep.2003.50446","article-title":"Patients with Primary Biliary Cirrhosis React Against a Ubiquitous Xenobiotic-Metabolizing Bacterium","volume":"38","author":"Selmi","year":"2003","journal-title":"Hepatology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1053\/j.gastro.2004.05.005","article-title":"Primary Biliary Cirrhosis in Monozygotic and Dizygotic Twins: Genetics, Epigenetics, and Environment","volume":"127","author":"Selmi","year":"2004","journal-title":"Gastroenterology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"814","DOI":"10.14309\/ajg.0000000000000604","article-title":"Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework","volume":"115","author":"Shah","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1053\/jhep.2000.8090","article-title":"Mimicry Peptides of Human PDC-E2 163-176 Peptide, the Immunodominant T-Cell Epitope of Primary Biliary Cirrhosis","volume":"31","author":"Shimoda","year":"2000","journal-title":"Hepatology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e112877","DOI":"10.1371\/journal.pone.0112877","article-title":"PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC)","volume":"9","author":"Stinton","year":"2014","journal-title":"PLoS ONE"},{"key":"B84","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1365-2249.2010.04288.x","article-title":"Autoantibodies to GW Bodies and Other Autoantigens in Primary Biliary Cirrhosis","volume":"163","author":"Stinton","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/cei.13198","article-title":"Pathogen Infections and Primary Biliary Cholangitis","volume":"195","author":"Tanaka","year":"2018","journal-title":"Clin. Exp. Immunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","article-title":"Gut Microbial Profile Is Altered in Primary Biliary Cholangitis and Partially Restored after UDCA Therapy","volume":"67","author":"Tang","year":"2018","journal-title":"Gut"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/hep.1840160616","article-title":"Susceptibility to Primary Biliary Cirrhosis Is Associated with the HLA-DR8-Dqb1*0402 Haplotype","volume":"16","author":"Underhill","year":"1992","journal-title":"Hepatology"},{"key":"B88","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/jalm\/jfab099","article-title":"The Role of Autoantibodies in the Diagnosis of Autoimmune Liver Disease: Lessons Learned from Clinical Practice","volume":"7","author":"van Beers","year":"2022","journal-title":"J. Appl. Laboratory Med."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/rheumatology\/kev438","article-title":"Predictors of Disease Relapse in IgG4-Related Disease Following Rituximab","volume":"55","author":"Wallace","year":"2016","journal-title":"Rheumatology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.autrev.2016.07.016","article-title":"The Clinical Presentation and Therapy of Diseases Related to Anti-Neutrophil Cytoplasmic Antibodies (ANCA)","volume":"15","author":"Weiner","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"B91","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/apt.16153","article-title":"Anti-Glycoprotein 2 (Anti-GP2) IgA and Anti-Neutrophil Cytoplasmic Antibodies to Serine Proteinase 3 (PR3-ANCA): Antibodies to Predict Severe Disease, Poor Survival and Cholangiocarcinoma in Primary Sclerosing Cholangitis","volume":"53","author":"Wunsch","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1002\/hep.31395","article-title":"Roles of Trained Immunity in the Pathogenesis of Cholangiopathies: A Therapeutic Target","volume":"72","author":"Yan","year":"2020","journal-title":"Hepatology"},{"key":"B93","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S2665-9913(19)30017-7","article-title":"Management of IgG4-Related Disease","volume":"1","author":"Zhang","year":"2019","journal-title":"Lancet Rheumatology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","article-title":"Interaction Between Microbiota and Immunity in Health and Disease","volume":"30","author":"Zheng","year":"2020","journal-title":"Cell Res."}],"container-title":["Frontiers in Molecular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmmed.2022.914505\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T03:38:26Z","timestamp":1657251506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmmed.2022.914505\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":94,"alternative-id":["10.3389\/fmmed.2022.914505"],"URL":"https:\/\/doi.org\/10.3389\/fmmed.2022.914505","relation":{},"ISSN":["2674-0095"],"issn-type":[{"value":"2674-0095","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]},"article-number":"914505"}}